Equities analysts expect Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) to post ($0.54) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Eiger BioPharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.58) and the highest estimate coming in at ($0.50). Eiger BioPharmaceuticals posted earnings of ($0.52) per share during the same quarter last year, which would suggest a negative year over year growth rate of 3.8%. The company is scheduled to report its next earnings report on Thursday, November 4th.
According to Zacks, analysts expect that Eiger BioPharmaceuticals will report full-year earnings of ($1.27) per share for the current financial year, with EPS estimates ranging from ($2.29) to ($0.70). For the next financial year, analysts anticipate that the business will post earnings of ($1.84) per share, with EPS estimates ranging from ($1.98) to ($1.75). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals (NASDAQ:EIGR) last posted its earnings results on Thursday, August 5th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.03).
EIGR stock traded down $0.15 during trading on Friday, hitting $7.13. The company had a trading volume of 5,353 shares, compared to its average volume of 211,853. The company has a quick ratio of 7.35, a current ratio of 7.48 and a debt-to-equity ratio of 0.29. The firm has a 50-day moving average price of $8.07 and a 200-day moving average price of $8.42. Eiger BioPharmaceuticals has a 12 month low of $7.22 and a 12 month high of $13.49. The stock has a market cap of $242.07 million, a price-to-earnings ratio of -8.88 and a beta of 1.34.
Hedge funds and other institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP boosted its holdings in shares of Eiger BioPharmaceuticals by 10.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 108,210 shares of the biotechnology company’s stock worth $1,330,000 after buying an additional 10,229 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Eiger BioPharmaceuticals during the first quarter valued at $39,000. Towerview LLC raised its holdings in Eiger BioPharmaceuticals by 7.7% in the first quarter. Towerview LLC now owns 140,000 shares of the biotechnology company’s stock worth $1,239,000 after purchasing an additional 10,000 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Eiger BioPharmaceuticals by 5.7% during the first quarter. BlackRock Inc. now owns 2,510,932 shares of the biotechnology company’s stock valued at $22,222,000 after acquiring an additional 135,646 shares in the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new position in shares of Eiger BioPharmaceuticals during the first quarter valued at about $136,000. Institutional investors and hedge funds own 68.68% of the company’s stock.
Eiger BioPharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.
See Also: Dead Cat Bounce
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eiger BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.